The Association between Age, Comorbidities and Use of Radiotherapy in Women with Breast Cancer: Implications for Survival

• Main Authors: Jimmy T. Efird, Sharyn Hunter, Sally Chan, Sarah Jeong, Susan L. Thomas, Charulata Jindal, Tithi Biswas
• Format: Article
• Language: English
• Published: MDPI AG 2018-06-01
• Series: Medicines
• Subjects: breast cancer; comorbidities; older women; radiotherapy; survival
• Online Access: http://www.mdpi.com/2305-6320/5/3/62

Background: Radiotherapy (RT) plays an important role in the management and survival of patients with breast cancer. The aim of this study was to examine the association between age, comorbidities and use of RT in this population. Methods: Patients diagnosed with breast cancer from 2004–2013 were identified from the American College of Surgeons National Cancer Database (NCDB). Follow-up time was measured from the date of diagnosis (baseline) to the date of death or censoring. Adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) were used as the measure of association. Results: Independently of comorbidities and other important outcome-related factors, patients >65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.